ACS Treatment Continues to Improve: But Price Matters

被引：2
|
作者：
Heuser, Richard R. [1 ,2 ]
机构：
[1] St Lukes Med Ctr, Cardiol, Quezon City, Philippines
[2] Univ Arizona, Coll Med Phoenix, Med, Tucson, AZ 85721 USA
来源：
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS | 2016年 / 88卷 / 04期
关键词：
PLATELET-AGGREGATION; INHIBITION; CLOPIDOGREL;
D O I：
10.1002/ccd.26790
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Over 90% of patients achieve adequate levels of platelet inhibition with both Prasugrel and Ticagrelor. The introduction of Prasugrel was met with some hesitation from physicians because of the significant increase in cost. This pharmaceutically sponsored and authored retrospective study suggests that both agents are effective. © 2015 Wiley Periodicals, Inc.
引用
收藏
页码：544 / 545
页数：2
相关论文
共 50 条
12345